AZD6094 (Volitinib)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for AZD6094 (Volitinib), covering 2019-12-30 to 2022-06-15. Get the full timeline:
Most recent: Clinical Trial Update: Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment [Phase 1, Phase 2]